Involvement of the ERK/HIF-1α/EMT Pathway in XCL1-Induced Migration of MDA-MB-231 and SK-BR-3 Breast Cancer Cells

被引:21
作者
Do, Ha Thi Thu [1 ,2 ]
Cho, Jungsook [1 ,2 ]
机构
[1] Dongguk Univ Seoul, Coll Pharm, Dongguk Ro 32, Goyang 10326, Gyeonggi, South Korea
[2] Dongguk Univ Seoul, Integrated Res Inst Drug Dev, Dongguk Ro 32, Goyang 10326, Gyeonggi, South Korea
关键词
chemokine; XCL1; XCR1; breast cancer cells; MDA-MB-231; cells; SK-BR-3; cell migration; ERK; HIF-1; alpha; EMT; EPITHELIAL-MESENCHYMAL TRANSITION; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CHEMOKINE RECEPTOR XCR1; TUMOR-METASTASIS; MAP KINASE; T-CELLS; EXPRESSION; LYMPHOTACTIN; CADHERIN; OVEREXPRESSION;
D O I
10.3390/ijms22010089
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chemokine-receptor interactions play multiple roles in cancer progression. It was reported that the overexpression of X-C motif chemokine receptor 1 (XCR1), a specific receptor for chemokine X-C motif chemokine ligand 1 (XCL1), stimulates the migration of MDA-MB-231 triple-negative breast cancer cells. However, the exact mechanisms of this process remain to be elucidated. Our study found that XCL1 treatment markedly enhanced MDA-MB-231 cell migration. Additionally, XCL1 treatment enhanced epithelial-mesenchymal transition (EMT) of MDA-MB-231 cells via E-cadherin downregulation and upregulation of N-cadherin and vimentin as well as increases in beta-catenin nucleus translocation. Furthermore, XCL1 enhanced the expression of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. Notably, the effects of XCL1 on cell migration and intracellular signaling were negated by knockdown of XCR1 using siRNA, confirming XCR1-mediated actions. Treating MDA-MB-231 cells with U0126, a specific mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, blocked XCL1-induced HIF-1 alpha accumulation and cell migration. The effect of XCL1 on cell migration was also evaluated in ER-/HER2(+) SK-BR-3 cells. XCL1 also promoted cell migration, EMT induction, HIF-1 alpha accumulation, and ERK phosphorylation in SK-BR-3 cells. While XCL1 did not exhibit any significant impact on the matrix metalloproteinase (MMP)-2 and -9 expressions in MDA-MB-231 cells, it increased the expression of these enzymes in SK-BR-3 cells. Collectively, our results demonstrate that activation of the ERK/HIF-1 alpha/EMT pathway is involved in the XCL1-induced migration of both MDA-MB-231 and SK-BR-3 breast cancer cells. Based on our findings, the XCL1-XCR1 interaction and its associated signaling molecules may serve as specific targets for the prevention of breast cancer cell migration and metastasis.
引用
收藏
页码:1 / 23
页数:20
相关论文
共 71 条
[41]   Chemokines and chemokine receptors: A new strategy for breast cancer therapy [J].
Liu, Hui ;
Yang, Zhenjiang ;
Lu, Wenping ;
Chen, Zhen ;
Chen, Lianyu ;
Han, Shuyan ;
Wu, Xiaoyu ;
Cai, Tiange ;
Cai, Yu .
CANCER MEDICINE, 2020, 9 (11) :3786-3799
[42]   Hypoxia-inducible factor 1 mediates intermittent hypoxia-induced migration of human breast cancer MDA-MB-231 cells [J].
Liu, Litao ;
Liu, Wenlan ;
Wang, Lili ;
Zhu, Ting ;
Zhong, Jianhua ;
Xie, Ni .
ONCOLOGY LETTERS, 2017, 14 (06) :7715-7722
[43]   Deferoxamine Promotes MDA-MB-231 Cell Migration and Invasion through Increased ROS-Dependent HIF-1α Accumulation [J].
Liu, Yiping ;
Cui, Yongfeng ;
Shi, Miao ;
Zhang, Qiang ;
Wang, Qiang ;
Chen, Xiaodong .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 33 (04) :1036-1046
[44]   Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition [J].
Mendez, Melissa G. ;
Kojima, Shin-Ichiro ;
Goldman, Robert D. .
FASEB JOURNAL, 2010, 24 (06) :1838-1851
[45]   The ethyl acetate fraction from Physalis alkekengi inhibits LPS-induced pro-inflammatory mediators in BV2 cells and inflammatory pain in mice [J].
Moniruzzaman, Md. ;
Bose, Shambhunath ;
Kim, Young-Mi ;
Chin, Young-Won ;
Cho, Jungsook .
JOURNAL OF ETHNOPHARMACOLOGY, 2016, 181 :26-36
[46]   Therapeutic targets in triple negative breast cancer [J].
O'Toole, Sandra A. ;
Beith, Jane M. ;
Millar, Ewan K. A. ;
West, Richard ;
McLean, Anna ;
Cazet, Aurelie ;
Swarbrick, Alexander ;
Oakes, Samantha R. .
JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (06) :530-542
[47]   Triple-negative breast cancer: investigating potential molecular therapeutic target [J].
Papa, Anselmo ;
Caruso, Davide ;
Tomao, Silverio ;
Rossi, Luigi ;
Zaccarelli, Eleonora ;
Tomao, Federica .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (01) :55-75
[48]   Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry [J].
Park, Seho ;
Koo, Ja Seung ;
Kim, Min Suk ;
Park, Hyung Seok ;
Lee, Jun Sang ;
Lee, Jong Seok ;
Kim, Seung Il ;
Park, Byeong-Woo .
BREAST, 2012, 21 (01) :50-57
[49]  
Prosperi JR, 2010, CURR DRUG TARGETS, V11, P1074
[50]   BMP9 Inhibits Proliferation and Metastasis of HER2-Positive SK-BR-3 Breast Cancer Cells through ERK1/2 and PI3K/AKT Pathways [J].
Ren, Wei ;
Liu, Yuehong ;
Wan, Shaoheng ;
Fei, Chang ;
Wang, Wei ;
Chen, Yingying ;
Zhang, Zhihui ;
Wang, Ting ;
Wang, Jinshu ;
Zhou, Lan ;
Weng, Yaguang ;
He, Tongchuan ;
Zhang, Yan .
PLOS ONE, 2014, 9 (05)